AlisonWLorenMD

Hematologic Oncology

Assistant Professor, Medicine, Perelman School of Medicine

Dr. Loren is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Civic Center Blvd
6th Floor South Tower
Philadelphia, PA 19104
Phone+1 215-662-2406

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Pennsylvania Health SystemResidency, Internal Medicine, 1996 - 2000
Washington University in St. Louis School of MedicineClass of 1996

PubMed

Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, Ronac Mamtani, Selina M Luger
Blood Advances. 2025-02-11
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko
Journal of Clinical Oncology. 2025-01-03
Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease.
Emily Baumrin, Peter F Cronholm, Matthew D Kearney, Mlka Mengesha, Laura G Cesar
JAMA Dermatology. 2025-01-02

Journal Articles

Harder to Treat Than Leukemia — Opioid Use Disorder in Survivors of Cancer
Alison Loren, MD, The New England Journal of Medicine

Penn Medicine at the 2024 ASH Annual MeetingDecember 2nd, 2024
Penn Medicine at the 2022 ASH MeetingDecember 8th, 2022
New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease After Stem Cell TransplantationJanuary 10th, 2022